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Abstract
Multiple myeloma is an incurable cancer of bone marrow plasma cells, with a 5-year survival rate of 43%. Its incidence
has increased by 126% since 1990. Treatment typically involves high-dose combination chemotherapy, but therapeutic
response and patient survival are unpredictable and highly variable—attributed largely to the development of
multidrug resistance (MDR). MDR is the simultaneous cross-resistance to a range of unrelated chemotherapeutic
agents and is associated with poor prognosis and survival. Currently, no clinical procedures allow for a direct,
continuous monitoring of MDR. We identified circulating large extracellular vesicles (specifically microparticles (MPs))
that can be used to monitor disease burden, disease progression and development of MDR in myeloma. These MPs
differ phenotypically in the expression of four protein biomarkers: a plasma-cell marker (CD138), the MDR protein,
P-glycoprotein (P-gp), the stem-cell marker (CD34); and phosphatidylserine (PS), an MP marker and mediator of cancer
spread. Elevated levels of P-gp+ and PS+ MPs correlate with disease progression and treatment unresponsiveness.
Furthermore, P-gp, PS and CD34 are predominantly expressed in CD138− MPs in advanced disease. In particular, a
dual-positive (CD138−P-gp+CD34+) population is elevated in aggressive/unresponsive disease. Our test provides a
personalised liquid biopsy with potential to address the unmet clinical need of monitoring MDR and treatment failure
in myeloma.
Introduction
Multiple myeloma (MM) is a neoplasia of terminally
differentiated plasma cells, characterised by the presence
of multiple bone marrow infiltrates1. It represents the
second most commonly diagnosed haematological
malignancy worldwide2, with 159,985 cases reported
globally in 20183. First-line treatment includes high-dose
combination chemotherapy with or without autologous
stem-cell transplant (ASCT). The presence of multisite
tumour infiltrates, each with differing degrees of drug
sensitivity4, contribute to a tumour heterogeneity and
variability in survival, ranging from a few weeks to more
than 10 years5–7. MM is also marked by multiple
recurrent episodes of remission and relapse, the latter
being a clinical manifestation of disease unresponsiveness
to treatment and resistance to chemotherapy8.
Multidrug resistance (MDR) is a unique type of resis-
tance in which cancer cells become cross-resistant to a
wide range of structurally and functionally unrelated
drugs usually following exposure to a single chemother-
apeutic agent9. One of the most important mechanisms by
which cancers acquire MDR is through the over-
expression of resistance proteins, belonging to the ATP
class of drug transporters, including P-glycoprotein
(P-gp)10. These are plasma membrane drug efflux trans-
porters that mediate the removal of chemotherapeutics
from the cancer cell plasma membrane10. Elevated P-gp
expression is correlated with poor prognosis and response
to chemotherapy across many cancers9. In the context of
MM, P-gp expression increases by up to 75% in patients
following treatment11. The utility of newer immunomo-
dulatory drugs and proteosome inhibitors are also
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compromised, with evidence that they are also P-gp
substrates12–14. Likewise, many of the agents typically
used in combination chemotherapy for MM are also P-gp
substrates. Currently, there is no procedure that supports
a minimally invasive and continuous monitoring for the
presence and development of MDR in MM during
treatment.
Microparticles (MPs) are a subset of extracellular vesi-
cles (0.1−1 µm in diameter) released from the plasma
membranes of most cell types15. MPs differ from other
extracellular vesicles by virtue of their size, biogenesis and
cargo16–18. Circulating MPs have been detected systemi-
cally for many cancers including MM, breast, prostate, and
lung cancer19–24. Their presence in blood make them
important components of the ‘tumour circulome’ and ideal
candidates as biomarkers in the context of a liquid biopsy25.
We discovered that cancer-derived MPs confer the
transfer and spread of MDR within cancer cell popula-
tions26–30 through the intercellular transfer of functional
resistance proteins and nucleic acids packaged within the
vesicular cargo26,27,30. Circulating MPs are hence pro-
mising surrogate markers of compartmentally confined
malignancies such as MM.
In our previous work, we demonstrated the clinical
feasibility of analysing circulating MPs in MM, whereby
the number of CD138+ circulating MPs was elevated in
MM patients across all stages of disease and corresponds
to plasma-cell burden and treatment response in indivi-
dual patients23.
We now expand on our initial findings and present a
novel blood test with capacity to continuously monitor
patients for the presence of MDR during treatment. This
minimally invasive blood test accounts for the presence of
multisite tumour infiltrates, can test for the presence of
MDR during routine follow-up and allows for simulta-
neous analysis of tumour burden. The technology com-
plements existing gold standard tests, has potential to




Annexin V-V450, anti-CD138-APC, anti-CD41a-PE,
anti-P-gp-FITC, anti-CD34-PE-Cy7, matched isotype
controls, BDTM CompBeads anti-mouse-Ig k, SpheroTM
Rainbow calibration particles and TruCountTM tubes
were from BD Biosciences (Sydney, NSW, Australia).
Latex beads of 0.3 and 1.1 µm diameter were from Sigma-
Aldrich (Sydney, NSW, Australia). Details of other
reagents used are described in Supplementary Table 1.
Study design and eligibility criteria
This study was approved by the Sydney Local Health
District Human Research Ethics Committee (HREC) of
Concord Repatriation General Hospital (CRGH) (HREC/
11/CRGH/223-CH62/6/2011-150), Royal Prince Alfred
Hospital (RPAH) HREC (SSA/12/RPAH/10) and the
University of Technology Sydney (2012-004R). Blood
samples were collected from myeloma patients and
healthy subjects (>18 years of age) after informed consent
at the CRGH and RPAH blood collection centres in
accordance with the Declaration of Helsinki. A pre-
determined sample size was not calculated as, being a
preliminary study, we analysed all available samples fol-
lowing informed consent. Study participants were de-
identified and assigned a code for access to clinical
information. Healthy subjects were age-matched, non-
cancer patients with normal haematology and devoid of
any cytotoxic treatment or radiotherapy of any nature
during the previous 5 years. Pregnancy was an exclusion
criterion. In total, we assessed three markers (P-gp,
CD138, PS) independently in 74 patients. Of the myeloma
cohort this included patients that were treatment
responsive (partial remission (n= 30) and complete
remission (n= 12)), de novo (n= 14) and relapsed (n=
18). We also assessed the complete signature comprising
four markers (P-gp, CD138, PS, CD34) in 11 patients.
Patient clinical response was established according to the
IMWG guidelines31,32.
Sampling, MP enrichment and immunolabelling
Following informed consent, 8 ml of blood was taken in
Ethylenediaminetetraacetic acid (EDTA) tubes from each
patient and healthy donors. The samples were assigned a
code with date and time of collection.
Platelet-free plasma (PFP) was prepared as previously
described33,34. Briefly, whole blood was centrifuged
immediately after sampling at 1500 × g for 20 min at room
temperature to remove cells, and the platelet-poor plasma
obtained was subsequently centrifuged at 13,000 × g for
2 min at room temperature to obtain PFP. The PFP was
divided into 200 µl aliquots and centrifuged at 18,890 × g,
4 °C for 30min to pellet the MP fraction. The samples
were analysed immediately after isolation or kept at
−20 °C until analysis. Prior to immunolabelling, frozen
samples were thawed on ice. Samples were resuspended in
500 µl cold PBS and spun at 18,890 × g, 30 min, 4 °C. After
removing the supernatant, the MP pellet was immunola-
belled by re-suspending the pellet with 20 µl of anti-
CD41a-PE antibody, 20 µl of anti-P-gp-FITC antibody,
5 µl of anti-CD138-APC and 5 µl of CD34-PE-Cy7 anti-
body for 30min in the dark at room temperature. The
same volumes and labelling conditions were performed
for the respective isotype-matched control antibodies
also. Following labelling, the pellet was washed with
500 µl ice-cold PBS and centrifuged at 18,890 × g for
30min at 4 °C. The pellet was subsequently resuspended
in 5 µl Annexin V-V450 and 5 µl Annexin Binding Buffer
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10× and incubated for 20min at room temperature in the
dark. The sample was then diluted by the addition of 500 µl
of Annexin V Binding Buffer 1×. Isotype-matched control
samples were resuspended in 500 µl PBS after staining. The
samples were transferred to BD Trucount™ Tubes (BD
Biosciences, Australia) for flow cytometric analysis.
Flow cytometric analysis
The phenotyping and quantitatation of MPs in patient
samples were performed using a Becton−Dickinson LSRII
and a Becton−Dickinson LSRFortessa X20 flow cyt-
ometer. Technical specifications and laser and filter con-
figurations for the channels used are outlined in
Supplementary Tables 2, 3. Flow cytometer setup was
performed using CS&T instrument setup beads (BD
Australia, North Ryde, NSW) following the manu-
facturer’s instructions. Triggering thresholds as well as
FSC and SSC voltages were set to exclude signal from PBS
alone. An MP size gate was defined on a FSC-A vs. SSC-A
dotplot by using 0.3 and 1.1 µm latex beads (Sigma-
Aldrich, Australia) as the lower and upper size limits,
respectively23. Compensation setup was performed using
CompBeads compensation particles (BD Australia, North
Ryde, NSW), following the manufacturer’s instructions.
Compensation matrices were calculated and applied using
the setup feature in the BD FACSDiva Software (Version
8.0.1). Laser performance was validated prior to each
experiment using Sphero Rainbow calibration particles
(BD Australia, North Ryde, NSW). A sequential gating
strategy using the MP size gate followed by gating for
CD41a− events (to exclude platelet-derived MPs) and
CD138+ was applied to MP populations. Further,
CD138+/− subpopulations were gated based on staining
for Pgp, CD34 and PS. The full gating strategy is shown in
Supplementary Fig. 1. Relevant isotype-matched and
unstained controls were included in the analysis. Total MP
counts comprised all CD41a− events in the MP size gate.
Samples were run at the lowest possible sample pressure and
flow rate (~8–12 µl/min) in order to minimise the occur-
rence of swarm detection and coincidence. Sample acquisi-
tion was performed using the collection of 2000−10,000
Trucount™ beads events as a stopping parameter.
Fluorescence positivity gates were set based on the back-
ground fluorescence observed in isotype-matched control or
unstained controls. Data analysis was performed using the
BD FACSDiva and CellQuest Pro softwares. MP Numbers
(MPs/µl) were calculated according to the Trucount™ tubes’
manufacturer’s formula: MPs/µl= [#MPs region of interest/
Trucount™ beads analysed] × [Trucount™ beads per tube/
Vol. sample added to Trucount™ tube].
Statistical analysis
Normality of data distribution for each group and each
parameter was assessed by performing a Shapiro−Wilk
test. The Mann–Whitney (U) test was performed for the
non-parametric data obtained. The software used for
statistical analysis was GraphPad Prism® version 7.0 for
Mac (GraphPad, La Jolla, CA, USA). Mann–Whitney
constant U and p value are also indicated. The results with
a two-tailed p value, p < 0.01(**) and p < 0.05 (*), were
considered significant.
Results
P-gp+ MPs are present in plasma of myeloma patients
MPs isolated from the plasma of myeloma patients and
healthy volunteers were immunophenotyped for the pre-
sence of P-gp. This is the first demonstration of the pre-
sence of the MDR protein P-gp on the surface of
circulating MPs in myeloma or in any other cancer. We
observed a 5.4-fold greater number of P-gp+ MPs in
myeloma patients relative to healthy subjects (Fig. 1a).
More specifically, P-gp+ MPs were 6.2- and 13.5-fold
higher in de novo and progressive disease (PD) patients,
respectively, compared to healthy subjects (Fig. 1b). There
was no significant difference in P-gp+ MP numbers
between patients in complete remission (CR) and partial
remission (PR) relative to healthy subjects (Fig. 1b).
CD138 and P-gp do not coexpress on MPs in myeloma
Patients
We observed no significant difference in CD138+ P-gp+
MPs between myeloma patients and healthy subjects
(Fig. 2a). We also observed no significant difference across
de novo, CR, PR and PD states relative to healthy subjects
(Fig. 2b). Conversely, we observed a significant 4.6-fold
increase in CD138− P-gp+ MPs in myeloma patients
relative to healthy subjects (Fig. 2c). The CD138− P-gp+
MP counts were 3.5 and 12.67-fold greater in de novo and
Fig. 1 P-gp+ MPs increase in MM. The P-gp+ MP counts in the total
MP population in MM patients and healthy subjects are shown.
a P-gp+ MP numbers were significantly greater in MM patients
relative to healthy subjects (p= 0.0071, U= 516). b P-gp+ MP
numbers were greater in de novo (p= 0.0032, U= 69) and
progressive disease (p= 0.0096, U= 96) patients relative to healthy
subjects. There was no significant difference in the P-gp+ MP numbers
between patients in partial remission (PR) or complete remission (CR)
and healthy subjects. Lines represent the mean values. p values were
determined by Mann–Whitney U. **p < 0.01.
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PD patients, respectively, compared to healthy subjects.
CD138− P-gp+ MP numbers were not significantly dif-
ferent in the CR or PR patient subsets relative to healthy
subjects (Fig. 2d).
An increase in PS+ MPs is associated with progressive
disease
PS is a phospholipid that is preferentially exposed at
high levels on the exoplasmic surface of cancer and
metastatic cell plasma membranes, and which is gaining
importance as a cancer cell targeting biomarker35.
Increased PS has been correlated with tumour aggressiv-
ity36 and its presence on MPs has been shown to be
associated with neovascularization through interactions
with vascular endothelial cells37. PS is also an MP marker,
its presence arising from the loss of phospholipid asym-
metry during MP biogenesis18. PS+ MP counts hence also
coincide with increased tumour burden.
Total PS+ MPs were significantly (6.4-fold) greater in
myeloma patients relative to healthy subjects (Fig. 3a). In
particular, PS+ MP counts were 3.4- and 3.6-fold greater
in the de novo and PR cohorts respectively, relative to
healthy volunteers (Fig. 3b). Most importantly, the PS+
MP counts were 16-fold higher in the PD cohort relative
to healthy subjects. We did not observe any significant
difference in counts between CR and healthy subjects (Fig.
3b). The PS+ MPs counts were significantly (7.78-fold)
higher in the PD cohort compared to the CR cohort (Fig.
3b) and this is consistent with disease progression and
increase in tumour burden.
PS co-localises with both CD138+ and CD138− MPs in
myeloma
Figure 4a shows the CD138+ PS+ MP counts of mye-
loma patients compared to healthy subjects. We observed
a significant 2.4-fold increase in CD138+ PS+ MPs in the
total patient cohort compared to healthy subjects. Speci-
fically, the de novo and PR cohorts showed a 3.3- and 3.4-
fold increase, respectively, in CD138+ PS+ MP. We
observed no significant difference in the CR or PD
patients relative to healthy subjects (Fig. 4b).
Figure 4c shows the CD138−PS+ MP counts of mye-
loma patients compared to healthy subjects. We
observed a significant 5.1-fold increase in CD138−PS+
MPs in patients compared to healthy subjects. The de
novo and PD patients had 7.6- and 8-fold greater
numbers of CD138− PS+ MPs, respectively, compared to
healthy subjects. We also observed significantly higher
numbers of CD138− PS+ MPs (2.9-fold) in PR patients
compared to healthy volunteers (Fig. 4d). We did not
observe any significant difference in CD138− PS+ MP
counts across patients in CR compared to healthy sub-
jects (Fig. 4d).
Fig. 2 CD138 and P-gp are not coexpressed on MPs. The numbers
of Pgp+ MPs in the context of CD138 expression are shown. a There
was no significant difference in CD138+ P-gp+ MP numbers in MM
patients relative to healthy subjects. b CD138+ P-gp+ MP numbers
across de novo, PR, CR and PD were not significantly different in MM
patients relative to healthy subjects. c CD138− P-gp+ MP numbers
were significantly greater in MM patients relative to healthy subjects
(p= 0.011, U= 541). d CD138− P-gp+ numbers were significantly
greater in de novo (p= 0.001, U= 81) and PD (p= 0.0379, U= 104)
patients compared to healthy volunteers and not significant for CR, PR
patients. Lines represent the mean values. p values were determined
by Mann–Whitney U. *p < 0.05; **p < 0.01.
Fig. 3 PS+ MPs represents a more aggressive state in MM. The
PS+ MP counts in MM patients and healthy subjects are shown. a PS+
MP counts were significantly greater in MM patients relative to healthy
volunteers (p= 0.005, U= 433). b PS+ MP counts were greater in de
novo (p= 0.0026, U= 60), PR (p= 0.03, U= 172), and PD (p= 0.005, U
= 85) cohorts relative to healthy volunteers. No significant difference
in PS+ MP counts was observed between the CR and healthy
volunteers. PS+ MPs counts were significantly higher in the PD cohort
compared to the CR cohort (p= 0.034, U= 54). p values were
generated using Mann–Whitney U test and the lines represent mean
values. *p < 0.05; **p < 0.01.
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A CD138− P-gp+ CD34+ MP signature corresponds to
disease progression and treatment unresponsiveness
Cancer stem cells are found in myeloma and many
cancers. These ‘side populations’, as they are often refer-
red to in flow cytometry, are characterised by: the pre-
sence of surface markers selectively expressed on cancer
stem cells, which are used to isolate these cells, and the
ability to extrude dyes such as Hoechst 33342. Stem cells
are typically resistant to chemotherapeutics, and in the
context of myeloma, are phenotypically CD138−34,38–40.
Likewise, CD34 is a well-established hematopoietic stem-
cell marker belonging to the CD34 family of sialomu-
cins41. CD34 is also expressed on a minor subpopulation
of myeloma stem-cell clones42.
We phenotyped for the presence of this MP signature in
11 myeloma patients during the course of treatment
(Table 1A, B). Table 1A details the MP phenotype of a
panel of five individual patients (patients 1–5), each
representative of a distinct clinical response state. The
study included patients with: (a) aggressive progressive
disease, patient 1; (b) progressive disease, patient 2
(Supplementary Fig. 2A, B); (c) stable disease, patient 3
(Supplementary Fig. 2C, D); (d) partial remission, patient
4 (Supplementary Fig. 3); (e) long-term survivor in
remission, patient 5. Table 1B shows the longitudinal
profile of the same MP markers in seven patients (patients
4, 6–11) during the course of treatment over time.
We observed that the CD138− P-gp+ CD34+ dual-
positive MP subpopulation was elevated in patients with
advanced aggressive/unresponsive/terminal disease (i.e.,
patients 6 and 1) relative to patients in remission or
those responsive to therapy (i.e., patients 4, 5, 8, 9, 10,
11). In the following sections, we provide details with
respect to patients 1 and 5 for simplicity, and which
Fig. 4 PS is enriched on CD138− MPs in progressive disease.
The numbers of PS+ MPs in context to the expression of CD138 are
shown. a PS+MPs in the CD138+ MP subset were significantly
elevated in MM patients compared to the healthy volunteers
(p= 0.0041, U= 405.5). b CD138+PS+MP levels in the de novo and
PR (p= 0.007, U= 134) cohorts were significantly higher relative to
healthy volunteers, while the differences between CR or PD and
healthy volunteers were not significant. c PS+MPs in the CD138−
MP subset were significantly elevated in MM patients relative to
healthy volunteers (p= 0.001, U= 406). d CD138−PS+ MPs were
significantly higher in de novo (p= 0.004, U= 80), PD (p= 0.001,
U= 52) and PR (p= 0.043, U= 180) cohorts relative to healthy
volunteers. There was no significant difference in CR cohort relative
to healthy volunteers. Mann–Whitney U test was conducted to
generate p values and the data are represented as mean. *p < 0.05;
**p < 0.01.
Table 1 A: MP signature in MM patients representative of different clinical response states.






















Patient 1 PD (Aggressive) 155.2 496.8 12.5 28.5 56.4 5 0.3 0.3 0 0
Patient 2 PD 60 40.5 4.78 74 60 1.1 0.5 5 3 0.4
Patient 3 Stable 6.3 5.13 4.7 18.5 23 1.6 0.2 1.2 1 0.3
Patient 4 PR 10 15.13 7.2 63 36.5 2.5 0.5 4 2.2 0.3
Patient 5 Remission (CR later) 6.3 5.13 2.5 14.4 53 0.5 3 4.5 2.4 1.17
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Table 1 B: Longitudinal evolution of MP signature in MM patients.



















Patient 4 (MM74) M 14/03/2014 Diagnosis 0.3 1.63 13.31 0.03 0.1 0.81 1.97 0.03
2/04/2014 CyBorD induction 1.83 16.1 43.1 0.03 0.13 0.88 2.64 0.03
29/04/2014 PR 1.9 8.05 299.58 0.1 0.47 0.47 10.56 0.16
6/05/2014 PR 7.09 14.7 322.88 0.27 0.64 0.61 18.88 0.37
10/06/2014 PR 5.12 27.07 387.52 1.32 1.66 2.3 20.14 1.42
17/06/2014 PR 4.61 27.1 258.82 1.15 1.73 4.48 37.39 1.35
30/06/2014 PR 1.76 10.69 49.65 1.52 2.34 5.23 9.61 1.69
21/07/2014 PR 1.18 2.71 31.45 0.23 0.5 1.18 6.24 0.33
Patient 6 (MM34) F 29/11/2013 PD (terminal) 122 775.32 238.44 3.46 4.51 4.92 3.6 3.66
13/12/2013 PD 152.17 788.73 208.99 7.91 9.13 17.59 4.6 8.35
17/01/2014 PD 77.57 312.01 69.32 5.97 6.89 13.65 4.5 6.08
20/02/2014 PD 61.68 130.66 207.84 6.89 7.81 5.36 12.73 6.99
11/03/2014 PD 98.8 485.65 150.64 6.55 9.17 10.25 8.79 6.79
Patient 7 (MM19) M 30/09/2013 Stable 38.17 177.54 43.4 5.06 6.24 8.79 10.12 5.26
4/11/2013 PD 27.78 223.7 58.04 3.49 4.1 6.48 8.76 3.63
Patient 8 (MM79) M 1/05/2014 PR 4.95 9.57 22.38 0.1 0.16 0.3 0.98 0.1
10/06/2014 PR 6.99 45.85 37.7 0.5 0.78 3.53 2.68 0.54
17/06/2014 PR 8.59 40.28 119.42 0.4 0.4 0.57 2.85 0.4
7/07/2014 PR 10.83 145.51 74.65 1.01 1.42 6.38 6.99 1.05
Patient 9 (MM49) M 3/03/2014 PR 4.27 16.5 31.55 0.4 0.61 2.13 2.27 0.47
5/05/2014 PD (suspecting) 6.18 15.55 21.43 1.15 1.56 2.41 1.35 1.32
Patient 10 (MM41) F 26/08/2013 PR 2.13 2.24 185.55 0.13 0.61 0.2 14.26 0.2
25/09/2013 ASCT 76.32 0.57 7.5 0.37 0.61 0.23 7.26 0.3
20/11/2013 PR 3.05 8.08 283.65 0.3 1.35 1.01 7.88 0.54
5/12/2013 PR 27.47 36.03 2861.08 3.43 4.07 0.84 70.2 3.43
14/02/2014 PR 6.08 11.2 721.72 0.37 5.12 0.61 48.67 0
14/03/2014 PR 2.71 2.37 205.6 0.74 1.22 0.23 15.35 0.98
4/04/2014 PR 1.32 2.24 237.25 0.16 0.98 0.3 15.52 0.27
13/05/2014 PR 4.48 3.56 269.32 0.74 1.42 0.27 34.03 0.98
10/06/2014 PR 0.44 1.18 216.02 0.2 0.57 0.33 12.49 0.33
10/07/2014 PR 3.83 7.23 185.11 0.44 1.01 0.91 9.2 0.54
3/10/2015 PR 0.78 2.41 212.29 0.78 1.22 0.5 36.14 0.81
Patient 11 (MM71) F 24/03/2014 De novo 47.04 32.84 586.29 1.05 1.52 0.27 11.07 1.25
24/04/2014 PR 2.92 5.36 118.71 0 0.03 0.03 0.95 0
23/05/2014 PR 3.1 8.01 25.16 0.13 0.23 0.78 2.75 0.13
Values are expressed as MP/μl.
MP microparticle, PD progressive disease, PR partial remission, CR complete remission.
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represent two clearly distinct clinical states. A more
detailed patient history of these and the other patients
examined as part of the longitudinal study are detailed in
Supplementary Materials 1, 2.
P-gp+ MP numbers in a 58-year-old female patient with
aggressive disease (patient 1)
Figure 5 represents the levels of different P-gp+ MP
subpopulations of patient 1 in response to treatment.
The patient’s total MPs were regularly phenotyped from
the day of diagnosis in September 2013. An initial
increase in P-gp+ MPs counts was evident 3 months
following the start of treatment (December 2013), and
this was elevated in the CD138− subpopulation (Fig. 5a).
At that time, the patient was in partial remission with a
corresponding 46% decrease in bone marrow plasmacy-
tosis from the initial 86% at diagnosis. A slight drop in
the CD138−Pgp+ MPs was observed after the start of
Thalidomide treatment in January 2014 (Fig. 5a).
CD138−Pgp+ MPs levels peaked again in February 2014,
although the patient was still in partial remission with
again a further reduction of bone marrow plasmacytosis of
23% in April 2014 and a stem-cell transplantation was
scheduled. However, the patient was found to have
relapsed by May−June 2014 consistent with the increase
in paraprotein. Consequently, we observed an increase of
the levels of CD138−Pgp+ MPs prior to the clinical
manifestation of relapse evidencing the capacity of the
signature to detect the transition between remission and
relapse before the existing clinical test used.
Following relapse, the treatment regimen was changed
to lenalidomide/dexamethasone from July until October
2014. The patient further relapsed in February 2015 with
a chest wall plasmacytoma, and the bone marrow plas-
macytosis was reported at 60%. This relapse correlated
with another increase in CD138−Pgp+ MPs. The addi-
tion of D-PACE and melphalan resulted in a partial
response in May 2015 and the patient was finally given
ASCT on 17 July 2015. The partial response obtained in
May 2015 correlated with a decrease in CD138−Pgp+
MPs. The transplant proved to be only transiently
effective and the patient presented with complicated
physical manifestations in October−November 2015,
became unresponsive to therapy, passing away in
December 2015.
The blood sample taken in February 2015, during PD
and prior to stem-cell transplantation, was also analysed
for CD34 and PS expression. Figure 6 shows the flow
cytometry cytograms including gating strategy used
(Fig. 6a). Figure 6b shows the presence of P-gp+, CD34+
and P-gp+CD34+ MPs, particularly evident in the
CD138− population. Total CD34+ (496.81/µl) and P-gp+
(155.29/µl) MP counts were higher relative to when the
patient was in PR in May 2015 (7.33/µl and 6.31/µl for
CD34+ and P-gp+, respectively, data not shown).
We compared the levels of CD34+ P-gp+ MPs on
CD138+ (Fig. 6b, right panel) and CD138− (Fig. 6b, left
panel) MP subpopulations. Figure 6b shows the strong
presence of the dual-positive CD138−P-gp+ CD34+
(Fig. 6b, left panel, gate P1, 12.48/µl) in this unresponsive
patient. In comparison, we detected small numbers of
CD138+ P-gp+ CD34+ MPs (Fig. 6b, right panel, gate P4,
0.30/µl). We also identified additional MP subsets which
were CD138− P-gp+CD34− (Fig. 6b, left panel, gate P3,
56.45/µl) and CD138− P-gp− CD34+ (Fig. 6b, right panel,
gate P2, 28.5/µl). We did not detect MPs within the
CD138+ population that were solely CD34+ or P-gp+
(Fig. 6b, right panel, gates P5 and P6).
The CD138− and CD138+ dual-positive MP sub-
populations were subsequently gated and phenotyped for
the presence of PS using Annexin V. We detected PS+
MPs within the CD138− P-gp+CD34+ MP population
(Fig. 6c, left panel, gate P11, 5/µl). We did not detect
Fig. 5 P-gp+MPs in a 58-year-old female patient with aggressive
disease (patient 1). The P-gp+ MP counts (Y-axis) and time of MP
sampling post diagnosis (X-axis) are shown. a CD138−P-gp+ MP
numbers during treatment (CyBorD, circle; BorD (Cyclophosphamide
discontinued), filled circle; VTD, triangle; lenalidomide/
dexamethasone, filled triangle; D-PACE and melphalan, diamond).
b CD138+ P-gp+ MP numbers during treatment.
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Annexin V-positive events on CD138+ P-gp+CD34+ MPs
(Fig. 6c, right panel, gate P12).
62-year-old male patient in remission—long-term survivor
(patient 5)
At the time of sampling on 5 May 2015, patient 5 was
responding well and eventually achieved stringent com-
plete remission with ongoing chemotherapy. This patient
is a long-term survivor (>10 years) with successful ther-
apeutic interventions. A flow cytometric scatter plot
depicting the different CD138+/− subpopulations for this
patient is shown in Fig. 7a, b. At the time of sampling we
detected lower CD34+ (5.13/µl) and P-gp+ MPs (6.3/µl)
numbers within the total MP population, in patient 5,
compared to patient 1. We also detected a consistently
lower number of dual-positive (CD138− P-gp+ CD34+)
MPs (Fig. 7a, left panel, gate P1, 2.54/µl) and a CD138+
P-gp+CD34+ MP population (Fig. 7a, right panel gate P4,
3.0/µl). We detected a subset of CD138− P-gp+CD34− MPs
(Fig. 7a, left panel, gate P3, 52.83/µl) and CD138− P-gp−
CD34+ MPs (Fig. 7a, left panel, gate P2, 14.46/µl). We also
observed a small subpopulation of CD138+ P-gp− CD34+
MPs (Fig. 7a, right panel, gate P5, 4.5/µl) and CD138+
P-gp+ CD34− MPs (Fig. 7a, right panel, gate P6, 2.4/µl).
The CD138 MP subpopulations were gated, phenotyped
and quantified for PS+ MPs. We detected a lower number
of CD138− P-gp+CD34+ PS+ MPs (Fig. 7b, left panel, gate
P11, 0.5/µl) and CD138+ P-gp+ CD34+ PS+ MPs (Fig. 7b,
right panel, gate P12, 1.17/ µl), compared to patient 1.
Discussion
We describe a liquid biopsy that monitors for the pre-
sence of an MDR biomarker ‘signature’. This minimally
Fig. 6 Increased ‘dual-positive’ MPs in aggressive disease (patient 1). P-gp+ and CD34+ MP counts in CD138− and CD138+ MP populations
were determined using flow cytometry. a A sequential gating strategy using MP size (left panel) followed by CD41a expression (middle panel) and
CD138 expression (right panel) was applied to the total MP population (left panel). The total MP population (CD41a−) was defined based on ±
staining for anti-CD41a (middle panel). b The total MP population was gated based on CD138 expression. We phenotyped for the presence of
CD138− P-gp+ CD34+ MPs (left panel, gate P1) and CD138+ P-gp+ CD34+ MPs (right panel, gate P4). c The CD138− P-gp+ CD34+ and CD138+
P-gp+ CD34+ MP subpopulations (gates P1 and P4 of left and right panel in b, respectively) were gated and phenotyped for PS+ events using
annexin V (left panel, gate P11; right panel, gate P12), respectively.
Fig. 7 62-year-old male patient in remission—long-term survivor
(patient 5). The presence of P-gp+ and CD34+ MPs in CD138− (left
panel) and CD138+ (right panel) MP populations was determined by flow
cytometry for patient 5. a The total MP population was gated based on
CD138 expression (left panel, CD138−; right panel, CD138+, respectively).
We phenotyped for CD138− P-gp+ CD34+ MPs (left panel, gate P1) and
CD138+ P-gp+ CD34+ MPs (right panel, gate P4). b The CD138 MP
subpopulations (gates P1 and P4 of left and right panel, respectively)
were also gated and phenotyped for the presence of PS using annexin V
(left panel, gate P11, events; right panel, gate P12), respectively.
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invasive test accounts for tumour heterogeneity char-
acteristic of multisite tumour infiltrates, can test for the
presence of MDR during routine follow-up and allows for
simultaneous analysis of disease burden. The test com-
plements existing gold standard tests, has potential to
support clinical staging criteria and streamlines easily into
existing hospital workflows.
We demonstrate for the first time the presence of cir-
culating MP subpopulations in the context of P-gp
expression in myeloma patients. We show that patients
have higher numbers of P-gp+ MPs compared to healthy
subjects, and this is associated with poor therapeutic
response. Our earlier work showed that MPs shed from
MDR cancer cells carry functional P-gp from the cell of
origin26,27. P-gp expression is typically induced in malig-
nant cells following drug exposure; however, it can also be
inherently expressed. This is consistent with our obser-
vation that 35% of the de novo patients had elevated
P-gp+ MP levels. Likewise, elevated P-gp+ MP levels were
also observed in patients with PD following treatment.
CD138 is the most useful marker for plasma cells and it
is the most appropriate when a single marker is used43.
However, we observed that P-gp+ MPs were pre-
dominantly CD138−. Within the total MP population, we
identified a number of different subpopulations based on
the expression of CD138, P-gp, CD34 and PS. Amongst
these, the presence of a ‘dual-positive’ (CD138−CD34+P-
gp+) population appears to be associated with an
unresponsive state.
The predominant expression of the aforementioned
markers in the CD138− subset of MPs may be a con-
sequence of CD138 shedding, which has been observed in
aggressive disease34.
Another possibility is the emergence of a ‘side popula-
tion’ composed of putative myeloma stem cells during
disease progression. These cells are typically CD138− and
express high levels of functional P-gp44–46. Lower
expression of CD138 on plasma cells is indicative of an
immature phenotype, poor prognosis and lower sensitivity
to lenalidomide treatment38–40.
The longitudinal data shown in Table 1B confirm the
predominance of CD138− subtypes in accordance with
clinical response states. For example, patient 6 (Supple-
mentary Fig. 4) is an MM patient with terminal disease.
Patient 6 underwent many different treatment regimens
and became treatment unresponsive. We observed ele-
vated counts of the ‘dual-positive’ (CD138− P-gp+CD34+)
MPs in this patient, which were higher relative to
treatment-responsive patients, further validating our
observations.
PS is an ubiquitous MP marker arising from the loss of
phospholipid asymmetry during MP biogenesis47. How-
ever, PS is not an absolute MP marker and its expression
is variable in MP populations48,49. Nevertheless, PS is
emerging as an important mediator in extracellular vesicle
biology and as a target in anticancer therapy. Its cell
surface presence was shown to enable cancer cell evasion
from physiological immune checkpoints50. Furthermore, a
recent study suggested a pro-angiogenic role for PS
exposed on MPs surface37. PS is also known to be a highly
immunosuppressive phospholipid51. Interestingly, the
exposure of PS on MPs was shown to contribute to
hypercoagulable states52, and higher rates of throm-
boembolic events have been associated with the use of
oral immunomodulatory drugs (IMiDs), thalidomide in
particular53. We observed significantly elevated PS+ MPs
across all disease stages except in CR, suggesting that their
levels may be associated with ‘active disease’ states. This
hypothesis is further corroborated by the significantly
higher PS+ levels we observed in PD compared to CR. We
also observed significantly greater numbers of PS+ MPs
among the CD138− MP population in some patients
(specifically, de novo and PD). In PD patients, the levels of
CD138− PS+ MPs may also be an indicator of tumour
burden.
Unlike P-gp, there was also a significantly greater
number of PS+ MPs in the CD138+ MP subpopulation in
MM patients relative to healthy subjects (specifically for
the de novo and PR cohort). PS+ events in the ‘dual-
positive’ MP population of the five patients examined
were in the following order: aggressive PD > PR > stable >
PD > remission patients (Table 1A). The significance of
the increased PS+ MP numbers in myeloma is currently
unknown and may be linked to the dissemination of
malignant cells to extramedullary sites during disease
progression37.
This study, together with our earlier work23, identifies
many MP subtypes in myeloma patients. CD138+ MPs
provide a marker of plasma-cell burden, while the pre-
sence of the ‘dual-positive’ MPs (CD138−CD34+P-gp+) of
‘stem-cell-like’ origin appear to be a marker of disease
progression and treatment unresponsiveness in patients,
specifically with aggressive disease.
CD138 cannot be considered a ‘static’ biomarker of MM
disease evolution as the presence of a CD138− population
increases in aggressive disease. This has important
implications in how we define the utility of biomarkers at
each stage of disease.
In conclusion, MPs provide a surrogate marker of their
cells of origin, which in the case of myeloma are pre-
dominantly confined to the bone marrow. We provide
evidence that MDR in patients with MM can be detected
and serially monitored by analysing MPs in blood samples
in the context of a ‘liquid biopsy’. Our results indicate the
presence of markers of MDR on MPs of stem-cell-like
origin. Stem cells are a reservoir of P-gp-positive cells, the
levels of which appear to correspond to disease progres-
sion. This has significant implications in the design of
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effective treatment strategies, including targeted approa-
ches against distinct cell clones with discrete phenotypes.
The shifting dominance of these signatures present at
various times must be considered during the design of
treatment interventions.
The work we present here depicts a personalised
approach with prognostic potential in determining the
presence of MDR in MM, whereby the development of
MDR can be serially and minimally invasively monitored
by analysing circulating MPs in the context of a liquid
biopsy. This work, besides introducing new exciting
insights into the molecular mechanisms contributing to
MDR and treatment failure in MM, demonstrates
potential as a new clinical test to complement existing
procedures used for the management of myeloma.
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